Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 15/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.38 |
| ▸ | HTR2A | P28223 | 3/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23710060 | 0.98 | — | — | |
| SCHEMBL185653 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL6025691 | 0.96 | SLC6A4 (0.39) | SLC6A2SLC6A4SLC6A3HTR2AADRB2 | |
| Morpholine SCHEMBL5147043 | 0.90 | MEN1 (0.39) | SLC6A2SLC6A4SLC6A3HTR2AADRB2 | |
| Hydrazine SCHEMBL8557573 | 0.88 | SLC6A2 (0.36) | SLC6A2SLC6A4SLC6A3HTR2AADRB2 | |
| Hydrazine SCHEMBL8557176 | 0.86 | SLC6A2 (0.36) | SLC6A2SLC6A4SLC6A3HTR2AADRB2 | |
| SCHEMBL20929877 | 0.86 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3HTR2AADRB2 | |
| SCHEMBL72780 | 0.86 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3HTR2AADRB2 | |
| Hydrazine SCHEMBL8555707 | 0.85 | EPHX1 (0.36) | SLC6A2SLC6A4SLC6A3HTR2AADRB2 | |
| Hydrazine SCHEMBL8558965 | 0.85 | EPHX1 (0.36) | SLC6A2SLC6A4SLC6A3HTR2AADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0575954-B1 | Aminoalkylcarbamic esters of eseroline suitable for use as cholinesterase acitivity inhibitors and relative preparation process | MEDIOLANUM FARMACEUTICI SRL (IT) | 1998-09-02 | — | — | EP | disclosed |